Royalty Pharma PLC $RPRX Shares Acquired by Capital International Ltd. CA

Key Points

• Capital International Ltd. CA increased its stake in Royalty Pharma by 47.6% in the fourth quarter, buying an additional 97,251 shares and bringing its total holding to 301,623 shares worth about $11.7 million.
• Royalty Pharma reported quarterly earnings of $1.30 per share, topping analyst estimates, though revenue of $630.6 million fell short of expectations.
• The company declared a quarterly dividend of $0.235 per share to be paid June 10, while analysts remain generally bullish with a consensus Buy rating and a target price of $53.71.

Capital International Ltd. CA lifted its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 47.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 301,623 shares of the biopharmaceutical company's stock after purchasing an additional 97,251 shares during the quarter. Capital International Ltd. CA owned about 0.05% of Royalty Pharma worth $11,655,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Lloyd Advisory Services LLC. acquired a new stake in shares of Royalty Pharma during the fourth quarter worth $30,000. Private Trust Co. NA boosted its holdings in shares of Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 288 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 790 shares during the last quarter. Larson Financial Group LLC boosted its holdings in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 306 shares during the last quarter. Finally, Fifth Third Bancorp boosted its holdings in shares of Royalty Pharma by 16.9% during the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company's stock worth $88,000 after purchasing an additional 362 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock opened at $55.87 on Friday. Royalty Pharma PLC has a twelve month low of $33.37 and a twelve month high of $56.07. The stock has a market capitalization of $32.17 billion, a P/E ratio of 38.01, a PEG ratio of 1.54 and a beta of 0.43. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The business's fifty day moving average price is $50.81 and its 200 day moving average price is $45.01.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The firm had revenue of $630.58 million for the quarter, compared to analysts' expectations of $881.69 million. As a group, research analysts anticipate that Royalty Pharma PLC will post 5.05 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be given a $0.235 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 annualized dividend and a yield of 1.7%. Royalty Pharma's dividend payout ratio (DPR) is 63.95%.

Insider Buying and Selling at Royalty Pharma

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the firm's stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total value of $161,385.00. Following the transaction, the director directly owned 191,803 shares of the company's stock, valued at $10,165,559. This trade represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the firm's stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $53.06, for a total value of $726,073.04. Following the completion of the transaction, the executive vice president directly owned 31,881 shares in the company, valued at $1,691,605.86. This trade represents a 30.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 199,185 shares of company stock valued at $10,082,926 over the last three months. 18.84% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on RPRX. The Goldman Sachs Group restated a "buy" rating on shares of Royalty Pharma in a report on Thursday, February 12th. Wall Street Zen upgraded Royalty Pharma from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 9th. Citigroup raised their price objective on Royalty Pharma from $50.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, May 7th. Weiss Ratings cut Royalty Pharma from a "buy (b)" rating to a "buy (b-)" rating in a report on Friday, May 15th. Finally, UBS Group lifted their target price on Royalty Pharma from $51.00 to $57.00 and gave the company a "buy" rating in a report on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $53.71.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.